6月 10日 (二)
7:30 am - 6:00 pm Registration Open
| 7:30 am Breakfast Workshop
|
Sponsored
by
|
8:15 Chairperson’s Remarks
8:20 Abacavir Case Study: From Biomarker Discovery to Clinical Utility
Eric H. Lai, Ph.D., Vice President, Pharmacogenetics, GlaxoSmithKline
This presentation will outline the path of a 7-year journey of a successful safety pharmacogenetics project from biomarker discovery to replication studies, prospective clinical trials and general application in clinical setting. It will highlight and compare candidate gene vs whole genome screening approaches and the changes in the scientific and regulatory landscapes in the past few years as related to the
application of pharmacogenetics in pharmaceutical development.
8:50 Genetic Variation and Drug Response, Some Recent Case Studies from AstraZeneca
Neil J. Gibson, Ph.D., Team Leader, R&D Genetics, AstraZeneca Pharmaceuticals
This presentation will illustrate a classic PGx efficacy study taking a candidate gene approach with one of our products. It will also highlight a genome-wide safety study with a Phase III compound and a next-generation sequencing approach looking for mutations in microbial genomes that are linked to drug sensitivity.
9:20 Novel Approaches to Personalized Medicine and Drug Discovery in Cancer: Predicting How Patients will Respond to Cancer Drugs
Dan Theodorescu, M.D., Ph.D., Director, Paul Mellon Prostate Cancer Institute, University of Virginia Health Sciences Center
Chemo-informatics-based approaches promise to make significant advances in oncology. Two areas where such approaches have been shown useful are individualized selection of optimal anticancer agents for common human tumors (i.e. personalized medicine) and virtual screening for the discovery of novel, high-quality lead compounds for the treatment of human cancer. The use of the newly developed “Co-eXpression ExtrapolatioN” (COXEN) principle to address these areas will be discussed.
9:50 Networking Coffee Break, Poster and Exhibit Viewing
10:45 Relevance of Adrenergic Receptor Polymorphisms to Heart Failure
Progression and Response to the Beta-Blocker, Bucindolol
J. David Port, Ph.D., Vice President Research & Technology, ARCA Discovery, Inc. and Professor of
Medicine/Cardiology and Pharmacology, University of Colorado HSC
This presentation will focus on the relevance of two well described adrenergic receptor polymorphisms and their relevance to cardiac function and biology. In each case, there are direct correlations between the biochemical and clinical phenotype observed with each polymorphism. In particular, these polymorphisms have been shown to profoundly affect the response of heart failure patients to the beta-blocker, bucindolol, thus, constituting important biomarkers for response to this drug.
11:15 The Genetic Landscape in Pediatric Cancer and Autism: Roles of Rare and Common Copy Number Variations in Disease Susceptibility
Hakon Hakonarson, Director, Center for Applied Genomics, The Children’s Hospital of Philadelphia
Genome-wide association (GWA) studies are rapidly replacing the more traditional candidate gene studies and microsatellite-based linkage mapping approaches that have dominated the gene discovery attempts for common diseases for many years. Large-scale SNP-based association mapping studies have now become feasible and over the last two years using this technology’s dramatic discoveries of key variants involved in multiple complex diseases have been reported
in the top scientific literature. This talk addresses genetic associations in pediatric cancer and in autism, demonstrating that apart from single SNP-based associations, the genetic landscape in these
disorders involves both rare and common copy number variations (CNVs) that predispose to these disorders.
11:45 Genome-Wide Association Scan in Women with Systemic Lupus Erythematosus Identifies Susceptibility Variants in ITGAM, PXK, KIAA1542 and Other Loci
Timothy W. Behrens, Ph.D., Genentech (invited)
12:15 pm Close of Genotyping and Large-Scale Association Studies
Conference
12:30 Luncheon Technology Workshops
(Sponsorships Available) or Lunch on Your Own
